Ramky Infrastructure FY26: Order Book Tops ₹13,000 Cr, Profitability Flattens

General information and entertainment, not investment advice. The author is not a SEBI-registered adviser or research analyst. No recommendation, no promised returns. Markets carry risk including loss of capital. Figures may not be current. Consult a registered adviser before acting.

1. At a Glance

The order book hit ₹13,000 crore in Q4, a milestone that should signal runway—but FY26 profit shrank 37% to ₹271 crore, and sales fell 10% to ₹1,846 crore.

The trouble isn’t demand. The company won big: ₹4,500 crore of fresh orders in Q4 alone, including a ₹3,000 crore pharma park concession and a ₹2,085 crore water HAM project in Hyderabad. The problem is execution timing. Large HAM projects reached their final stage, new contracts sit in engineering phase, and high-margin work from prior years didn’t repeat.

Operating margins compressed hard. Excluding other income, operating profit fell sharply. Debt tightened. Yet management guided ₹2,400 crore revenue for FY27—a notable lift.

The question underneath: is the cash generation machine just pausing, or has the model changed?

2. Introduction

Ramky Infrastructure spent three decades building water projects, industrial parks, roads, and buildings across India. The last two years rewrote the script. After debt restructuring, the company logged a ₹1,150 crore profit spike in FY23 (mostly other income and gains), trimmed that to ₹308 crore in FY24, then sagged to ₹271 crore in FY26.

The whiplash is real. But the underlying operational story—steady orders, selective focus on high-margin O&M contracts—remains intact. In May 2026, the board approved a 10% final dividend, the first in years. The company secretary resigned on May 26, to be relieved June 30. Rating agency Infomerics upgraded the credit rating in March from BBB- to BBB.

Geography remains concentrated: Andhra Pradesh (49%) and Telangana (33%) account for 82% of pending orders. Two major debt settlements closed (Srinagar–Banihal road in January 2024, Visakha Pharmacity sold in March 2026 for ₹165 crore). Capex discipline tightened. The company is exploring non-traditional funding structures and eyeing a Middle East/Africa footprint for water and desalination projects.

3. Business Model: WTF Do They Even Do?

Construction and developer—that’s the split. Construction (EPC) is 72% of the book. Developer (PPP, concessions, SPVs) is 28%.

The order book breaks down: Industrial solutions (43%, or ₹4,000 cr), water & wastewater (29%, or ₹2,700 cr), buildings (22%, or ₹2,000 cr), urban/other (5%, or ₹500 cr).

Inside that, EPC is ₹5,200 crore (execution-heavy, lower margins on industrials but fat on water), and O&M is ₹4,000 crore (30-year contracts, annuity income, the cash engine). The company treats HAM projects as leverage: 40% client-funded during construction, 30% equity, 70% debt. That debt sits on the balance sheet until operations begin.

The business mix matters. HAM work is capital-intensive upfront, but it de-risks revenue. EPC is lumpier but faster. The company is doubling down on water—explicitly stated as a first-mover advantage—and industrial parks, where it holds special claim (Visakha, Dighi, the new ₹3,000 crore pharma park in Maharashtra). Building work is treated as portfolio ballast, not the prize.

Equipments (₹250 cr of rigs, plants, pavers) sit on the balance sheet but aren’t a moat. The real advantage is track record—30 years, 450+ projects, 185 water completions, ₹350 acres of developed industrial parks. Management in-houses most work, hiring specialists selectively, to control capex, timelines, and opex.

4. Financials Overview

Figures are consolidated, in ₹ crore.

Yearly Results

FY26 sales contracted 10% YoY. Operating profit fell 31%. Net profit rose 29%—a statistical illusion. The profit bump came from lower interest (₹73 cr vs ₹120 cr), and a higher-than-expected tax benefit (negative tax of ₹11.77 cr in Q4 FY26, suggesting loss carryforwards or timing relief). Strip away interest and tax moves, and the core business softened.

EPS for FY26: ₹39.17 (full-year basis, not Q4 ×4). At the lagged price of ₹428.30, the P/E reads as 428.30 ÷ 39.17 = 10.9x, a significant discount to the peer band.

Quarterly Momentum (H1 FY27 preview)

Management guided FY27 revenue at ₹2,400 crore (or ₹2,200 cr excluding other income). H1 FY27 already posted ₹800 crore, implying ₹1,600 crore for H2—a ramp-up from H1 FY26’s ₹835 crore. New large contracts are in engineering stage; execution is expected to accelerate in Q3–Q4 FY27.

5. Valuation Discussion: Fair Value Range (Educational Only)

What follows is a walkthrough of how three valuation methods work, using this company’s numbers as the example — not a